通过对2-苯甲酰基吡啶硫代半碳a(HBpT),2-(3-硝基苯甲酰基)吡啶硫代半碳((HNBpT)和二吡啶基酮硫代半碳((HDpT)系列铁(Fe)螯合剂的系统结构活性研究,我们确定了形成Fe螯合剂所必需的结构特征配合物有效的抗癌活性(药物化学杂志。2007年,50,3716-3729)。在这项研究中,我们产生了相关的2-乙酰基吡啶硫半碳zone(HApT)类似物,以检查甲基对亚胺碳的影响。六个HApT螯合剂中的四个具有强大的抗肿瘤活性(IC 50:0.001-0.002μM)和Fe螯合功效,与最有效的HBpT和HDpT配体相似。HApT铁络合物的Fe III / II含量最低我们产生的任何硫代半碳carb系列的氧化还原电势。这种特性与有效螯合细胞铁的能力相结合,使HApT系列成为我们小组开发的最有效的抗增殖剂之一。
2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity
作者:Des R. Richardson、Danuta S. Kalinowski、Vera Richardson、Philip C. Sharpe、David B. Lovejoy、Mohammad Islam、Paul V. Bernhardt
DOI:10.1021/jm801585u
日期:2009.3.12
to the most effective HBpT and HDpT ligands. The HApT Fe complexes had the lowest FeIII/II redox potentials of any thiosemicarbazone series we have generated. This property, in combination with their ability to effectively chelate cellular Fe, make the HApT series one of the most potent antiproliferative agents developed by our group.
通过对2-苯甲酰基吡啶硫代半碳a(HBpT),2-(3-硝基苯甲酰基)吡啶硫代半碳((HNBpT)和二吡啶基酮硫代半碳((HDpT)系列铁(Fe)螯合剂的系统结构活性研究,我们确定了形成Fe螯合剂所必需的结构特征配合物有效的抗癌活性(药物化学杂志。2007年,50,3716-3729)。在这项研究中,我们产生了相关的2-乙酰基吡啶硫半碳zone(HApT)类似物,以检查甲基对亚胺碳的影响。六个HApT螯合剂中的四个具有强大的抗肿瘤活性(IC 50:0.001-0.002μM)和Fe螯合功效,与最有效的HBpT和HDpT配体相似。HApT铁络合物的Fe III / II含量最低我们产生的任何硫代半碳carb系列的氧化还原电势。这种特性与有效螯合细胞铁的能力相结合,使HApT系列成为我们小组开发的最有效的抗增殖剂之一。
[EN] CHEMICAL ACTIVATORS OF NICOTINAMIDE MONONUCLEOTIDE ADENLYLY TRANSFERASE 2 (NMNAT2) AND USES THEREOF<br/>[FR] ACTIVATEURS CHIMIQUES DE MONONUCLÉOTIDE DE NICOTINAMIDE ADÉNYLYL TRANSFÉRASE 2 (NMNAT2) ET LEURS UTILISATIONS
申请人:UNIV TSINGHUA
公开号:WO2020107221A1
公开(公告)日:2020-06-04
The present application relates to novel semicarbazones and thiosemicarbazones, to processes for preparing them, to pharmaceutical preparations comprising them, to the use of the novel semicarbazones and thiosemicarbazones for treatment and/or prophylaxis of diseases and to the use thereof for production of a medicament for treatment and/or prophylaxis of diseases, especially of neurodegeneration and age-associated diseases or conditions associated with NAD loss. The present application also provides a method for high throughput screening of NMNAT2 activators.